Skip to content
OpenCapital
Get started

Zymeworks ZYME Proceeds from maturities of marketable securities

Proceeds from maturities of marketable securities at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$143.8M-24.3%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$2.92M+82.4%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's proceeds from maturities of marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's proceeds from maturities of marketable securities?
Zymeworks (ZYME) reported proceeds from maturities of marketable securities of $70.18M in Q1 2026.
How has Zymeworks's proceeds from maturities of marketable securities changed year-over-year?
Zymeworks's proceeds from maturities of marketable securities increased by 50.7% year-over-year, from $46.55M to $70.18M.
What does proceeds from maturities of marketable securities mean?
Cash inflows resulting from the sale, redemption, or maturity of marketable securities held by the company. This metric indicates the conversion of investment assets back into cash to fund operations or other strategic needs.